New Technology May Replace Tissue Biopsies – Proxy Life Science Holdings Awarded Patent for RNA Exosome-Based Diagnostics

Share Article

Proxy Life Science Holdings receives approval of a gateway patent for its Proxysome™ virtual biopsy technology. Using a simple blood test, the technology promises not only to detect early disease but also to pinpoint the affected organ/tissue. This is a unique and advantageous capability among blood-based tests. New applications for a wide array of diseases are being discovered, including cardiovascular, immunological, neurological and cancer.

Proxy Life Science Holdings Incorporated (Proxy) announced today that that the US Patent and Trademark Office has issued Proxy a patent on its virtual biopsy technology. The technology has been shown to have the potential to identify the disease, its stage and the affected organ through a simple blood test. US Patent No. US 8,021,847 entitled “Microvesicle-Based Compositions and Methods“ relates to methods of isolating RNA from bloodborne exosomes and microvesicles for the detection and analysis of disease biomarkers which may then be traced back to the affected cells and organs which produced them.

The company has coined the term Proxysomes™ to describe what are commonly known as microvesicles and exosomes in academic circles. Proxysomes™ are nano- and micro-sized vesicle structures produced by cells, especially in response to disease, infection or stress. They are expelled from the affected cells and circulate in the blood stream and other bodily fluids. Importantly, Proxysomes™ share certain structures and components in common with their parental cells. They are essentially rich packets of circulating information loaded with a myriad of molecular markers such as mRNA, microRNA, proteins, and other cellular components. These biological structures have been shown to be at least in part, a fundamental communication mechanism between cells, a way for cells to shuttle SOS distress signals across short and long distances, a means to influence or even control the response of distant cells and tissues. This abundant source of information may also be decoded and translated to identify disease-related biomarkers, tissue-type biomarkers and their bio-signatures. This data can then be used to pinpoint an affected organ and determine its health or disease status, giving Proxysomes™ the potential to replace certain tissue biopsies with a virtual blood-based test.        

“By gathering Proxysomes™ via a simple blood draw, we can access information about distant cells, tissues and organs, including those originating from a multitude of diseases. Proxysomes™ have been associated with cancer as well as immunological, cardiovascular, aging and neurological conditions, just to name a few. Unlike a tissue biopsy, Proxysomes™ may be collected repeatedly, allowing for the dynamic monitoring of disease progression as well as therapeutic response and drug safety. These capabilities are just not practical and in most cases not possible with tissue biopsies. We believe our biopsyless method will prove to be an essential healthcare tool” stated Dr. Pietrzkowski, President and Co-founder.

“Academia has taken notice of the fundamental value of microvesicle and exosomes and has responded with a flurry of exciting publications in recent years. The implications for diagnostics, therapeutics, and drug delivery are truly tremendous. Our Proxysome™ platform has the potential to significantly advance the field of molecular diagnostics enabling significant advances in personalized medicine. We are very fortunate to have anticipated this value and to have secured one of the earliest and broadest patents in the field. With the issuance of this first gateway patent, our company is firmly positioned to be a leader in the rapidly developing field.” stated Mr. Rey Magana, Vice President and Co-founder.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rey Magana
rey@proxydx.com
(619) 723-4173
Email >
Visit website